Previous in vitro studies demonstrated that immunotargeting CD98hc using monoclonal antibodies and CAR T cells enhanced immune effector functions against numerous cancer cell lines, including melanoma, ovarian, breast and colorectal cancer cells [71]. Here, SLC3A2 is linked to melanoma.